SEARCH

SEARCH BY CITATION

References

  • 1
    Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, et al.: CRUSADE Investigators: The implications of blood transfusions for patients with non–st-segment elevation acute coronary syndromes: results from the crusade national quality improvement initiative. J Am Coll Cardiol 2005; 46: 14901495.
  • 2
    EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 16891696.
  • 3
    EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 8792.
  • 4
    Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, et al.: Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial Investigators: Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907919.
  • 5
    Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 14641476.
  • 6
    Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, et al., SYNERGY Trial Investigators: Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 4554.
  • 7
    Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, et al.: Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 13621368.
  • 8
    Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, et al., CRUSADE Investigators: Excess dosing of antiplatelet and antithrombin agents in the treatment of non–ST-segment elevation acute coronary syndromes. JAMA 2005; 294: 31083116.
  • 9
    Milkovich G, Gibson G: Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60(Suppl 3): S15S21.
  • 10
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, et al.: Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774782.
  • 11
    Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930935.
  • 12
    Nelson MA, Voeltz MD, Feit F, Lincoff AM, Manoukian SV: Elderly patients with major bleeding or need for transfusion complicating percutaneous coronary intervention have an increased risk of 30-day and 1-year mortality. Circulation 2006; 114: II687.
  • 13
    Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, et al., REPLACE-2 Investigators: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005; 95: 581585.
  • 14
    Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, et al.: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 27692775.
  • 15
    Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, et al.: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 18151823.
  • 16
    Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, et al., TIMI Study Group: Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006; 47: 23742379.
  • 17
    McDaniel MC, Fazel R, Voeltz MD, Feit F, Lincoff AM, et al.: Eptifibatide plus heparin increases the risk of major and minor hemorrhagic complications compared to bivalirudin in patients with normal renal function undergoing percutaneous coronary intervention. Circulation 2006; 114: II731.
  • 18
    Voeltz MD, Feit F, Stone GW, Manoukian SV: Anemia and outcomes in acute coronary syndromes. Acute Coron Synd 2005; 7: 4755.
  • 19
    Voeltz MD, Patel AD, Feit F, Fazel R, Lincoff AM, et al.: Effect of anemia on hemorrhagic complications and mortality in patients undergoing percutaneous coronary Intervention. Am J Cardiol 2007; 99: 15131517.
  • 20
    Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, et al.: Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 20422049.
  • 21
    Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, et al.: Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. Am J Med 2006; 119: 70.e1e8.
  • 22
    Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, et al.: Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995; 91: 28822890.
  • 23
    Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, et al.: Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 1998; 81: 3640.
  • 24
    Voeltz MD, Nelson MA, McDaniel MC, Manoukian SV: The important properties of contrast media: focus on viscosity. J Invasive Cardiol 2007; 19(A): 1A9A.
  • 25
    Hamon M, Sabatier R, Zhao Q, Niculescu R, Valette B, et al.: Mini-invasive strategy in acute coronary syndromes: direct coronary stenting using 5 Fr guiding catheters and transradial approach. Catheter Cardiovasc Interv 2002; 55: 340343.
  • 26
    Attubato MJ, Feit F, Bittl JA: Major hemorrhage is an independent predictor of 1 year mortality following percutaneous coronary intervention: an analysis from REPLACE-2. Am J Cardiol 2004; 946(1): 39E.
  • 27
    Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, et al.: Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 12001206.
  • 28
    Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 15551562.
  • 29
    Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, et al.: Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994998.
  • 30
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al., REPLACE-2 Investigators: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853863.
  • 31
    Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al., ACUITY Investigators: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 22032216.
  • 32
    Stone GW. A prospective, randomized trial of bivalirudin in acute coronary syndromes: final one-year results from the ACUITY trial. Presented at: 56th Annual Session of the American College of Cardiology; March 26, 2007; New Orleans, LA, Available at: http:// www.cardiosource.com/annualmtg /acc07/Lectures.asp?sessiontitle = LateBreaking%20Clinical%20 Trials %20Follow-Up&SessionID = 22&date = 3/26/2007 Accessed April 1, 2007.